Which Treatment for Which Lesion: Role of Multiple Stents and Zilver PTX DESs (Cook) For Long Lesions

Gary M Ansel MD
System Medical Chief: Vascular
OhioHealth/Riverside Methodist Hospital
Columbus, Ohio

Gary M Ansel MD.
Conflicts of Interest

- Consultant
  - Abbott Vascular
  - Boston Scientific
  - Cordis Corporation
  - Medtronic
  - WL Gore
  - CR Bard
  - Primacea
  - Venarum
  - Volcano/Philips
  - Novate
  - Reflow Medical

- Equity
  - Embolitech
  - Primacea
  - Reflow Medical

November 2018

BMS: Lesion Length Affects Patency Outcomes

Data from Superb, Durability II, Complete SE, Zilver BMS, and Vibrant Trials

5-year Primary Patency (PSVR < 2.0)
Zilver PTX vs. Standard Care

Zilver PTX
From 1-5 years, the relative separation increases by 33%
Optimal PTA + BMS

Zilver PTX RCT vs Impact RCT (Freedom from TLR 5-Year)

Lutonix 5 year? (cmon man!)
Illuminate 5 year still pending
Generalizability?
Zilver PTX Global Data Analysis

4. High rate of freedom from TLR
5. Nearly 2400 patients
6. 5-year results

Factors With Most Impact on TLR

**Symptomatic InStent Restenosis Pattern Results**

<table>
<thead>
<tr>
<th>Zilver PTX</th>
<th>BMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average days to TLR</td>
<td>18.8</td>
</tr>
<tr>
<td>Average stented length (mm)</td>
<td>15.8</td>
</tr>
<tr>
<td>Plaque burden (% area)*</td>
<td>28%</td>
</tr>
</tbody>
</table>

* p<0.05, statistically significant

**AND ITS BEATING THE GOLD STANDARD**
DES vs “Prosthetic Bypass” (ZILVERPASS STUDY)

<table>
<thead>
<tr>
<th>Zilver PTX</th>
<th>BMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plaque burden (% area)</td>
<td>39%</td>
</tr>
<tr>
<td>Relative reduction in plaque burden with Zilver PTX compared to BMS</td>
<td>35%</td>
</tr>
</tbody>
</table>
**FULL DRUG JACKET**  
**Single Center Experience**

- N = 89, First year of Zilver PTX use  
- Cut off for short vs full length 20 cm  
  - Average lesion length in short group = 13.9 cm  
  - Average lesion length in long group = 33 cm  
- Limitation of available stent lengths of only 80 cm

**Ansel et al J EVT 2018**

---

**Full Drug Jacket**  
**2-Year Results**

<table>
<thead>
<tr>
<th>Freedom From TLR</th>
<th>Short, Medium and Full Drug Jacket</th>
<th>Summary</th>
<th>DES and “Dont Stent” argument?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="image">Graph</a></td>
<td></td>
<td><a href="image">Graph</a></td>
</tr>
<tr>
<td></td>
<td><a href="image">Graph</a></td>
<td></td>
<td><a href="image">Graph</a></td>
</tr>
<tr>
<td></td>
<td><a href="image">Graph</a></td>
<td></td>
<td><a href="image">Graph</a></td>
</tr>
</tbody>
</table>

- Stent Fractures  
- Very low fracture rates
- Difficult to treat restenosis  
- Only bad technique takes away surgical options
- Leave Surgical option  
- Low and Less plaque burden
- Appears to be as good as prosthetic surgical bypass

---

**WE lead in vascular care**

**OHIOHEALTH VASCULAR INSTITUTE**